Growth Metrics

Merck (MRK) Cash from Financing Activities (2016 - 2026)

Merck has reported Cash from Financing Activities over the past 18 years, most recently at -$3.0 billion for Q1 2026.

  • Quarterly Cash from Financing Activities rose 48.2% to -$3.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $852.0 million through Mar 2026, up 108.54% year-over-year, with the annual reading at -$1.9 billion for FY2025, 72.67% up from the prior year.
  • Cash from Financing Activities was -$3.0 billion for Q1 2026 at Merck, down from $4.8 billion in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $4.8 billion in Q4 2025 and troughed at -$5.8 billion in Q1 2025.
  • The 5-year median for Cash from Financing Activities is -$2.4 billion (2024), against an average of -$1.5 billion.
  • Year-over-year, Cash from Financing Activities skyrocketed 311.48% in 2023 and then tumbled 392.43% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.6 billion in 2022, then tumbled by 44.47% to -$2.2 billion in 2023, then tumbled by 34.03% to -$3.0 billion in 2024, then surged by 257.89% to $4.8 billion in 2025, then crashed by 162.74% to -$3.0 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Cash from Financing Activities are -$3.0 billion (Q1 2026), $4.8 billion (Q4 2025), and $2.6 billion (Q3 2025).